Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 20,000 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Elizabeth Reed sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $45.00, for a total transaction of $900,000.00. Following the sale, the insider owned 105,211 shares of the company’s stock, valued at $4,734,495. This represents a 15.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Trading Down 0.2%

Shares of NASDAQ TVTX traded down $0.10 during midday trading on Wednesday, reaching $44.70. 2,390,035 shares of the stock were exchanged, compared to its average volume of 2,890,153. The company has a 50 day simple moving average of $32.59 and a 200 day simple moving average of $32.83. The stock has a market capitalization of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $48.61.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business’s revenue was up 55.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.47) EPS. As a group, equities analysts expect that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TVTX. Canaccord Genuity Group raised their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. JPMorgan Chase & Co. cut their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, March 25th. Wedbush raised their price target on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a report on Tuesday. TD Cowen raised their price target on shares of Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Wall Street Zen downgraded shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $47.83.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a “buy” rating, implying meaningful upside vs. current levels — a bullish signal from a major sell?side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an “overweight” rating, another near?term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi?year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year?over?year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre?arranged Rule 10b5?1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new stake in Travere Therapeutics during the 2nd quarter worth approximately $33,000. Fifth Third Bancorp acquired a new position in shares of Travere Therapeutics in the first quarter worth $35,000. First Horizon Corp acquired a new position in shares of Travere Therapeutics in the third quarter worth $36,000. State of Wyoming purchased a new stake in shares of Travere Therapeutics during the fourth quarter worth $37,000. Finally, Torren Management LLC purchased a new stake in shares of Travere Therapeutics during the fourth quarter worth $38,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.